ストックスクリーナーアプリを入手
14.04
2.70%
0.38
前日終値:
$13.66
開ける：
$13.94
24時間の取引高:
258.17K
Relative Volume:
0.19
時価総額：
$1.55B
収益：
$-665.00K
当期純損益:
$-144.74M
株価収益率:
-9.0423
EPS:
-1.5527
ネットキャッシュフロー:
$-123.48M
1週間 パフォーマンス:
+1.73%
1か月 パフォーマンス:
-2.37%
6か月 パフォーマンス:
+1.51%
1年 パフォーマンス:
+271.14%
1日の値動き範囲:
$13.80
$14.27
1週間の範囲:
$13.20
$14.44
52週間の値動き範囲:
$3.11
$17.49
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
名前
Amylyx Pharmaceuticals Inc
セクター
電話
617-682-0917
住所
55 CAMBRIDGE PARKWAY, CAMBRIDGE
Compare AMLX vs TAK, ZTS, HLN, TEVA, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
14.03 | 1.51B | -665.00K | -144.74M | -123.48M | -1.5527 |
TAK
Takeda Pharmaceutical Co Adr
|
18.31 | 56.99B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
115.80 | 48.94B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.77 | 43.30B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.85 | 33.94B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
546.66 | 23.31B | 3.18B | 1.33B | 1.04B | 27.90 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-03 | 開始されました | Stifel | Buy |
| 2025-07-10 | 再開されました | Goldman | Buy |
| 2025-06-24 | 開始されました | Guggenheim | Buy |
| 2025-06-17 | 開始されました | Citigroup | Buy |
| 2025-05-30 | 開始されました | TD Cowen | Buy |
| 2025-04-07 | アップグレード | Mizuho | Neutral → Outperform |
| 2024-11-18 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2024-10-23 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-03-18 | ダウングレード | Mizuho | Buy → Neutral |
| 2024-03-11 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-03-11 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-03-08 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-03-08 | ダウングレード | Goldman | Buy → Neutral |
| 2024-01-03 | 開始されました | Robert W. Baird | Outperform |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-07-24 | アップグレード | Goldman | Neutral → Buy |
| 2023-03-31 | 開始されました | Mizuho | Buy |
| 2023-01-05 | 開始されました | BofA Securities | Buy |
| 2022-05-25 | 開始されました | Citigroup | Buy |
| 2022-04-01 | ダウングレード | Goldman | Buy → Neutral |
すべてを表示
Amylyx Pharmaceuticals Inc (AMLX) 最新ニュース
HC Wainwright Reaffirms Buy Rating for Amylyx Pharmaceuticals (NASDAQ:AMLX) - MarketBeat
H.C. Wainwright reiterates Amylyx stock rating on trial progress By Investing.com - Investing.com Australia
Amylyx Pharmaceuticals Advances Novel Therapies for Rare Diseases: Avexitide, AMX0035, and AMX0114 Show Promise in Clinical Trials for PBH, Wolfram Syndrome, and ALS - Minichart
Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia - BioSpace
Amylyx Highlights Pipeline Progress in Updated Corporate Presentation - TipRanks
Amylyx Pharmaceuticals completes enrollment in Phase 3 LUCIDITY trial for PBH - Traders Union
Amylyx updates presentation: LUCIDITY and LUMINA enrollment complete; LUCIDITY topline due Q3 2026 - TradingView
Amylyx (NASDAQ: AMLX) details avexitide Phase 3 timing and cash runway into 2028 - Stock Titan
Amylyx Pharmaceuticals Q4 2025 earnings preview - MSN
Amyotrophic Lateral Sclerosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharmaceuticals - Barchart.com
Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Price Expected to Rise, Guggenheim Analyst Says - MarketBeat
Amylyx Pharmaceuticals Inc (AMLX) Shares Gap Down to $13.78 on M - GuruFocus
Maven Securities LTD Makes New $951,000 Investment in Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
Fund Flows: Is Amylyx Pharmaceuticals Inc stock a smart retirement pickPortfolio Gains Report & Weekly Sector Rotation Insights - baoquankhu1.vn
Amylyx shares slip despite Q4 beat as investors focus on trial timeline - MSN
Amylyx Pharmaceuticals expands team to address urgent healthcare challenges - Traders Union
How Investors May Respond To Amylyx Pharmaceuticals (AMLX) Narrowed 2025 Losses And Expanded Shelf Capacity - simplywall.st
Buy Rating on Amylyx Pharmaceuticals Driven by Avexitide’s Commercial Potential and De-Risked Phase III PBH Program - TipRanks
First Light Asset Management LLC Purchases Shares of 3,355,882 Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Amylyx Pharmaceuticals, Inc. $AMLX Shares Sold by Boxer Capital Management LLC - MarketBeat
Commodore Capital Boosts Stake in Amylyx Pharmaceuticals - National Today
Commodore Capital LP Purchases Shares of 4,075,478 Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
Braidwell LP Acquires Shares of 612,841 Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
437,391 Shares in Amylyx Pharmaceuticals, Inc. $AMLX Purchased by Ally Bridge Group NY LLC - MarketBeat
Amylyx Pharmaceuticals Inc (AMLX) Shares Down 3.06% on Mar 13 - GuruFocus
Amylyx anticipates LUCIDITY trial results in Q3 2026 while advancing PBH market strategy - MSN
Amylyx Pharmaceuticals (NASDAQ:AMLX) Shares Gap DownHere's What Happened - MarketBeat
Amylyx Pharmaceuticals Highlights Avexitide LUCIDITY Phase 3 Enrollment, Q3 Data Timing at Leerink Conf. - Yahoo Finance
Amylyx Pharmaceuticals Maps High-Stakes Path to 2027 - TipRanks
[Form 4] Amylyx Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Amylyx (NASDAQ: AMLX) CFO receives new stock options and RSU grant - Stock Titan
Wall Street Zen Upgrades Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Rating - National Today
Amylyx Pharmaceuticals (AMLX) Price Target Increased by 17.82% to 15.17 - MSN
Winners Losers: How Amylyx Pharmaceuticals Inc. stock performs in weak economy2025 Market Sentiment & Real-Time Volume Surge Alerts - Naître et grandir
Amylyx Pharmaceuticals, Inc. $AMLX Position Increased by Vanguard Group Inc. - MarketBeat
Amylyx Pharmaceuticals (NASDAQ:AMLX) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Q1 EPS Forecast for Amylyx Pharmaceuticals Lifted by Analyst - MarketBeat
Amylyx (AMLX) Q4 2025 Earnings Call Transcript - AOL.com
H.C. Wainwright raises Amylyx stock price target to $34 on trial confidence - Investing.com India
H.C. Wainwright raises Amylyx stock price target to $34 on trial confidence By Investing.com - Investing.com South Africa
Amylyx Pharmaceuticals Inc (AMLX) Q4 2025 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
Amylyx Leadership Triggers Buzz With Major Insider Stock Moves - TipRanks
Amylyx (AMLX) -7.8%: Earnings Show $0 Revenue, Shelf Filing Adds Dilution Fear - Trefis
Amylyx: LUCIDITY Trial Sets Stage For Q3 Inflection Point (NASDAQ:AMLX) - Seeking Alpha
Tax-withholding sale by Amylyx Pharmaceuticals (AMLX) Chief Legal Officer - Stock Titan
Amylyx (AMLX) Co-CEO sells shares to cover RSU tax withholding - Stock Titan
Amylyx Pharmaceuticals (AMLX) CEO share sale covers tax obligations - Stock Titan
Amylyx (AMLX) CFO reports automatic tax-related sale of 7,909 shares - Stock Titan
Amylyx Pharmaceuticals (NASDAQ:AMLX) Price Target Raised to $34.00 - MarketBeat
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q4 2025 Earnings Call Transcript - Insider Monkey
Amylyx Pharmaceuticals Inc (AMLX) 財務データ
収益
当期純利益
現金流量
EPS
Amylyx Pharmaceuticals Inc (AMLX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Cohen Joshua B | Co-Chief Executive Officer |
Mar 02 '26 |
Sale |
14.48 |
29,282 |
424,120 |
3,334,683 |
| Bedrosian Camille L | Chief Medical Officer |
Mar 02 '26 |
Sale |
14.58 |
6,461 |
94,205 |
169,295 |
| FRATES JAMES M | Chief Financial Officer |
Mar 02 '26 |
Sale |
14.52 |
7,909 |
114,851 |
165,638 |
| Mazzariello Gina | Chief Legal Officer |
Mar 02 '26 |
Sale |
14.52 |
6,844 |
99,378 |
134,430 |
3.23%
大文字化:
|
ボリューム (24 時間):